Estimated effects for ICBT and control group | |||||||
---|---|---|---|---|---|---|---|
Mean ICBTa (SD) | Mean controla (SD) | Diff.a | Coeff. | ESb | 95% CI for ES | p-value | |
TLFB-G (SEK) | |||||||
Posttreatment | 544 (1732) | 356 (707) | 188 | 0.67c | (0.11, 4.25) | ||
6 weeks | 49.2 (72.9) | 70.4 (95.1) | −21.2 | 2.01c | (0.71, 20.11) | ||
NODS | |||||||
Posttreatment | 3.33 (3.75) | 3.82 (3.41) | −0.49 | 0.37 | 0.18 | (−1.09, 1.46) | 0.77 |
6 weeks | 2.44 (3.13) | 2.00 (3.00) | 0.44 | −0.33 | −0.16 | (−1.85, 1.52) | 0.84 |
PGSI | |||||||
6 weeks | 10.0 (7.35) | 9.2 (7.49) | 0.8 | 1.01 | 0.26 | (−1.25, 1.78) | 0.72 |
GUS | |||||||
Posttreatment | 6.6 (8.54) | 6.7 (8.56) | −0.07 | −0.7 | −0.08 | (−0.80, 0.64) | 0.82 |
6 weeks | 10.7 (12.30) | 3.67 (11.00) | 7.03 | −7.79 | −0.89 | (−2.34, 0.55) | 0.21 |
GASS | |||||||
Posttreatment | 67.2 (28.00) | 61.1 (33.50) | 6.10 | −1.38 | −0.06 | (−1.11, 0.98) | 0.91 |
6 weeks | 77.7 (20.30) | 70.1 (37.10) | 7.6 | 1.12 | 0.05 | (−0.86, 0.96) | 0.91 |
PHQ-9 | |||||||
Posttreatment | 8.6 (6.73) | 9.2 (6.41) | −0.66 | 1.11 | 0.17 | (−0.59, 0.93) | 0.66 |
6 weeks | 5.2 (6.18) | 5.6 (5.53) | −0.34 | 2.27 | 0.37 | (−0.51, 1.26) | 0.38 |
GAD-7 | |||||||
Posttreatment | 6.8 (4.43) | 8.5 (5.89) | −1.70 | 2.28 | 0.43 | (−0.24, 1.09) | 0.20 |
6 weeks | 3.7 (4.23) | 3.7 (5.89) | 0 | 0.21 | 0.04 | (−0.83, 0.91) | 0.93 |
AUDIT-C | |||||||
Posttreatment | 2.8 (2.37) | 3.7 (2.82) | −0.90 | 0.41 | 0.18 | (−0.48, 0.85) | 0.58 |
6 weeks | 2.1 (2.09) | 2.2 (1.30) | −0.11 | 0.04 | 0.02 | (−0.53, 0.57) | 0.94 |